Sam Mouli's guest appearances

Sam Mouli

BackTable Vascular & Interventional

David Sacks

John Martin

David Wood

David Kim

Karen Brown

Justin Lee

David Liu

Eric Keller

Preston Smith

David Ball

Mike Watts

Chris Thomson

Susan Jackson

John Lipman

Aaron Shiloh

OwlTail

In this episode, host Dr. Michael Barraza interviews interventional radiologist Dr. Samdeep Mouli about controversies in prostate artery embolization, including technique, durability, and how we can leverage the data to unite IRs and establish PAE as standard of care.---CHECK OUT OUR SPONSORBoston Scientific Embold Fibered Coilshttps://www.bostonscientific.com/en-US/products/embolization/embold-detachable-coil-system.html---SHOW NOTESDr. Mouli discusses his role as director of translational research in interventional radiology at Northwestern. He reviews the most recent major data on PAE. There have been two major papers, one from a Portuguese group and another from a Brazilian group. The take home points from these papers are regarding the durability of symptoms and the safety profile of PAE. The biggest positive of PAE is that it is the safest among all minimally invasive surgeries. Dr. Mouli argues that PAE should be pursued as first line treatment for benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTs). Another upside of PAE is that it doesn’t prevent patients from undergoing any other medical or surgical intervention in the future.One of the barriers to PAE becoming first line therapy is that there is currently no standardization among operators. Everyone still does it differently, whether by using different microcatheters, particle sizes, or other technical factors. This gives urologists ground to stand on when they argue against PAE. Dr. Mouli feels IRs should approach BPH with the same rigor that urologists do. He believes we need to use the long-term data to prove that PAE is safe, durable and yields better sexual outcomes than TURP or other minimally invasive surgical procedures. This can be accomplished via publishing guidelines for IRs. He believes a good starting place is to only use 300-500 micron particles for de-novo PAE cases. It has been proven this size is safe and results in very low non-target embolization compared to the 100-300 micron size, which more commonly causes this complication and results in more sexual dysfunction.Dr. Mouli says urologists are pushing for surgical intervention before exhausting medical management and argues that IRs should do the same. He believes offering PAE early is in the best interest of patients, because waiting to fail medical management can cause further complications. Dr. Mouli does not get pre-procedure vascular imaging or MRI. This is because he uses intra-procedure cone beam CT. He does this as part of his procedure to map out collaterals and other blood supply to the prostate. He then targets these arteries with coils before using particle embolization on the prostate gland itself. He does this because his goal is to match the 5 year success rate demonstrated in recent studies of over 80 percent, with a less than 20% recurrence rate. He ends by stating that the long-term data show a 10-30% re-treatment rate across all treatment modalities. Knowing this, he feels even stronger that PAE should be the first line therapy, considering it is the least invasive option, it is safe and has the lowest rates of sexual dysfunction. If patients prefer more invasive procedures in the future, they can still go that route, or they can elect for repeat PAE as needed.---RESOURCESTriago Bilhim Paper:https://link.springer.com/article/10.1007/s00270-022-03199-8Francisco Carnevale Paper:https://pubmed.ncbi.nlm.nih.gov/33308534/UK-ROPE Study:https://pubmed.ncbi.nlm.nih.gov/29645352/

In this episode, host Dr. Michael Barraza interviews interventional radiologist Dr. Samdeep Mouli about controversies in prostate artery embolization, including technique, durability, and how we can leverage the data to unite IRs and establish PAE as standard of care. --- CHECK OUT OUR SPONSOR Boston Scientific Embold Fibered Coils<a href="https://www.bostonscientific.com/en-US/products/embolization/embold-detachable-coil-system.html" rel="nofollow" target="_blank">https://www.bostonscientific.com/en-US/products/embolization/embold-detachable-coil-system.html</a> --- SHOW NOTES Dr. Mouli discusses his role as director of translational research in interventional radiology at Northwestern. He reviews the most recent major data on PAE. There have been two major papers, one from a Portuguese group and another from a Brazilian group. The take home points from these papers are regarding the durability of symptoms and the safety profile of PAE. The biggest positive of PAE is that it is the safest among all minimally invasive surgeries. Dr. Mouli argues that PAE should be pursued as first line treatment for benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTs). Another upside of PAE is that it doesn’t prevent patients from undergoing any other medical or surgical intervention in the future. One of the barriers to PAE becoming first line therapy is that there is currently no standardization among operators. Everyone still does it differently, whether by using different microcatheters, particle sizes, or other technical factors. This gives urologists ground to stand on when they argue against PAE. Dr. Mouli feels IRs should approach BPH with the same rigor that urologists do. He believes we need to use the long-term data to prove that PAE is safe, durable and yields better sexual outcomes than TURP or other minimally invasive surgical procedures. This can be accomplished via publishing guidelines for IRs. He believes a good starting place is to only use 300-500 micron particles for de-novo PAE cases. It has been proven this size is safe and results in very low non-target embolization compared to the 100-300 micron size, which more commonly causes this complication and results in more sexual dysfunction. Dr. Mouli says urologists are pushing for surgical intervention before exhausting medical management and argues that IRs should do the same. He believes offering PAE early is in the best interest of patients, because waiting to fail medical management can cause further complications. Dr. Mouli does not get pre-procedure vascular imaging or MRI. This is because he uses intra-procedure cone beam CT. He does this as part of his procedure to map out collaterals and other blood supply to the prostate. He then targets these arteries with coils before using particle embolization on the prostate gland itself. He does this because his goal is to match the 5 year success rate demonstrated in recent studies of over 80 percent, with a less than 20% recurrence rate. He ends by stating that the long-term data show a 10-30% re-treatment rate across all treatment modalities. Knowing this, he feels even stronger that PAE should be the first line therapy, considering it is the least invasive option, it is safe and has the lowest rates of sexual dysfunction. If patients prefer more invasive procedures in the future, they can still go that route, or they can elect for repeat PAE as needed. --- RESOURCES Triago Bilhim Paper:<a href="https://link.springer.com/article/10.1007/s00270-022-03199-8" rel="nofollow" target="_blank">https://link.springer.com/article/10.1007/s00270-022-03199-8</a> Francisco Carnevale Paper:<a href="https://pubmed.ncbi.nlm.nih.gov/33308534/" rel="nofollow" target="_blank">https://pubmed.ncbi.nlm.nih.gov/33308534/</a> UK-ROPE Study:<a href="https://pubmed.ncbi.nlm.nih.gov/29645352/" rel="nofollow" target="_blank">https://pubmed.ncbi.nlm.nih.gov/29645352/</a>

Ep. 280 Current Controversies in Prostatic Artery Embolization with Dr. Sam Mouli

Reflect on how this Podcast applies to your day-to-day and earn AMA PRA Category 1 CMEs here: https://earnc.me/xI8Csf﻿Interventional Radiologists Dr. Sam Mouli from Northwestern University and Dr. Sandeep Bagla discuss new research examining Y-90 Radioembolization as a novel therapeutic option for treating prostate cancer.

Reflect on how this Podcast applies to your day-to-day and earn AMA PRA Category 1 CMEs here: <a href="https://earnc.me/xI8Csf" rel="nofollow" target="_blank">https://earnc.me/xI8Csf</a>﻿Interventional Radiologists Dr. Sam Mouli from Northwestern University and Dr. Sandeep Bagla discuss new research examining Y-90 Radioembolization as a novel therapeutic option for treating prostate cancer.

Ep. 78 Is Radioembolization a Future Option for Prostate Cancer Therapy? with Dr. Sam Mouli